81 SUBCUTANEOUS INTERLEUKIN-4 FOR RELAPSED NON-HODGKIN'S LYMPHOMA: A PHASE II TRIAL IN THE NORTH CENTRAL CANCER TREATMENT GROUP, NCCTG 91-78-51
| Autor: | S. M. Geyer, G. S. Soori, R. C. Tenglin, J. B. Allred, W. D. Putnam, T. E. Witzig, M. Wiesenfeld, K. M. Rowland, Paul J. Kurtin, D. M. Kurtz, A. M. Bernath, L. K. Tschetter |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Phases of clinical research Histology General Medicine medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Surgery Lymphoma Cytokine Refractory Internal medicine Edema Toxicity medicine Stage (cooking) medicine.symptom business |
| Zdroj: | Journal of Investigative Medicine. 55:S362.1-S362 |
| ISSN: | 1708-8267 1081-5589 |
| Popis: | Purpose Interleukin-4 (IL-4) is a pleiotropic cytokine that has in vitro antiproliferative activity against non-Hodgkin9s lymphoma (NHL). This phase II study was conducted to learn the efficacy and toxicity of IL-4 on patients with relapsing or resistant NHL. Patients and Methods Patients with relapsed or refractory indolent or aggressive NHL were eligible to receive either 2.5 or 5.0 μg/kg of subcutaneous IL-4 daily for 28 days of a 42-day cycle. Patients with a response and acceptable toxicity after two cycles were eligible to continue treatment for a total of six cycles followed by observation without maintenance. Results Forty-one patients were enrolled and were assessable for toxicity; two patients were ineligible after histology review, leaving 39 patients for the analysis of tumor response. The median age was 65 years (range 34-79 years), and 56% were stage 4. The overall response rate was 13% (5 of 39), with one complete response and four partial responses. All five responders were in the 5.0 μg/kg group, the median time to progression in all patients was 84 days, and the median duration of response for the responders was 8.3 months (range 7.4-15.7 months). Edema was noted in 66% (27 of 41) and was the most common toxicity. Conclusions Agents that target the IL-4 receptor can have therapeutic benefit in patients with relapsed or refractory NHL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|